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OBJECTIVES In this study we considered the question of whether adjunction of glucose-insulin-potassium
(GIK) infusion to primary coronary transluminal angioplasty (PTCA) is effective in patients
with an acute myocardial infarction (MI).
BACKGROUND A combined treatment of early and sustained reperfusion of the infarct-related coronary artery
and the metabolic modulation with GIK infusion has been proposed to protect the ischemic
myocardium.
METHODS From April 1998 to September 2001, 940 patients with an acute MI and eligible for PTCA
were randomly assigned, by open-label, to either a continuous GIK infusion for 8 to 12 h or
no infusion.
RESULTS The 30-day mortality was 23 of 476 patients (4.8%) receiving GIK compared with 27 of 464
patients (5.8%) in the control group (relative risk [RR] 0.82, 95% confidence interval [CI]
0.46 to 1.46). In 856 patients (91.1%) without signs of heart failure (HF) (Killip class 1),
30-day mortality was 5 of 426 patients (1.2%) in the GIK group versus 18 of 430 patients
(4.2%) in the control group (RR 0.28, 95% CI 0.1 to 0.75). In 84 patients (8.9%) with signs
of HF (Killip class 2), 30-day mortality was 18 of 50 patients (36%) in the GIK group
versus 9 of 34 patients (26.5%) in the control group (RR 1.44, 95% CI 0.65 to 3.22).
CONCLUSIONS Glucose-insulin-potassium infusion as adjunctive therapy to PTCA in acute MI did not result
in a significant mortality reduction in all patients. In the subgroup of 856 patients without
signs of HF, a significant reduction was seen. The effect of GIK infusion in patients with
signs of HF (Killip class 2) at admission is uncertain. (J Am Coll Cardiol 2003;42:
784–91) © 2003 by the American College of Cardiology Foundation
Since the early 1960s, glucose-insulin-potassium (GIK)
infusion has been advocated as therapy in the early hours
after acute myocardial infarction (MI) (1–4). An overview
involving nine of these early studies with 1,932 patients
described that GIK might play an important role in
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reducing in-hospital mortality after acute MI (5). In four
studies in which a high dose was used, a nonsignificant
reduction in mortality from 12% in the control group to
6.5% in the GIK group was observed (6–9). High-dose
GIK denotes an infusion of 30 g of glucose, 50 U of insulin,
and 80 mmol potassium per liter at a rate of 1.5 ml/kg body
weight/h (10). This suppresses arterial free fatty acid levels
and myocardial free fatty acid uptake, and induces a maxi-
mal increase in myocardial glucose uptake. The main effect
of the GIK infusion was considered to be the beneficial
effect of administration of glucose to the ischemic myocar-
dium (11–14).
At present, primary coronary transluminal angioplasty
(PTCA) is regarded to be the most effective reperfusion
treatment of acute MI (15–17). The complementary role of
GIK to reperfusion therapy has been proposed (18,19).
Therefore, we performed a randomized trial to investigate
the value of GIK when combined with PTCA for acute MI.
METHODS
Patients. All consecutive patients with symptoms consis-
tent with acute MI of 30 min duration, presenting within
24 h after the onset of symptoms and with an ST-segment
elevation of more than 1 mm (0.1 mV) in two or more
contiguous leads on the electrocardiogram, or new onset left
bundle branch block, were evaluated for inclusion in this
single-center study. Patients presented at our center and
patients referred for treatment of high-risk myocardial
infarction (MI) from nine referring hospitals without an-
gioplasty facilities were included. Patients were excluded
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when pre-treated with thrombolysis or when an illness
associated with a marked restricted life expectancy was
present. Before randomization baseline characteristics were
recorded. The research protocol was reviewed and approved
by the medical ethics committee of our hospital, and
patients were included after informed consent.
Protocol. After admission, patients were randomly as-
signed, with the use of a computerized randomization
program, to either GIK infusion or no infusion. In the GIK
group, a continuous infusion of 80 mmol potassium chloride
in 500 ml 20% glucose with a rate of 3 ml/kg body weight/h
over an 8- to 12-h period in a peripheral venous line was
given, as soon as possible. A continuous infusion of short-
acting insulin (50 U Actrapid HM, Novo Nordisk, Copen-
hagen, Denmark) in 50 ml 0.9% sodium chloride was
started with the use of a pump (Perfusor-FM, B. Braun,
Melsungen, Germany). Baseline insulin-infusion dose and
hourly adjustments of the insulin dose were based on a
nomogram (20) to obtain blood-glucose levels between 7.0
and 11.0 mmol/l, based on measurements of whole-blood
glucose (Modular System, Roche/Hitachi, Basel, Switzer-
land). Additional treatment in all patients consisted of
intravenous heparin, nitroglycerin, and aspirin.
After the infusion was started, all patients went to the
catheterization laboratory where both coronary arteries were
visualized; PTCA was performed with standard techniques
if the coronary anatomy was suitable for angioplasty. Suc-
cessful reperfusion was defined by Thrombolysis In Myo-
cardial Infarction grade 3 blood flow in combination with
myocardial blush grades 2 and 3 (21,22). After sheath
removal, low-molecular-weight heparin was given for 1 to 3
days.
Statistical analysis. The primary end point of the study
was 30-day mortality. Secondary end points were recurrent
infarction, repeat coronary angioplasty, and the composite
incidence of death, recurrent infarction, or repeat coronary
angioplasty. The incidence of death was evaluated in pre-
defined subgroups including age 60 years versus 60
years, men versus women, anterior MI versus nonanterior
MI, diabetics versus nondiabetics, Killip class 1 versus Killip
class 2, and successful reperfusion versus no successful
reperfusion. Analyses were performed according to the
intention-to-treat principle. Relative risks (RRs) were cal-
culated by dividing the cumulative incidence rate in the
GIK group by the cumulative incidence rate in the control
group. Differences between group means at baseline were
assessed with the two-tailed Student t test. Chi-square
analysis or Fisher exact test was used to test differences
between proportions. Survival was calculated by the Kaplan-
Meier product-limit method. The log-rank test was used to
evaluate differences in survival curves between the two
treatment groups. The Cox proportional-hazards regression
model was used to calculate RRs adjusted for differences in
baseline characteristics. Statistical significance was consid-
ered a two-tailed p value  0.05. The SPSS Version 10.1
(SPSS Inc., Chicago, Illinois) was used for all statistical
analysis.
Power analysis. We postulated that GIK would induce a
risk reduction of 66% (19). With an estimated absolute
mortality rate of 6% in the control group, a power of 0.80
and an alpha of 0.05, 820 patients needed to be included in
the study. In order to have 820 patients in each major
predefined subgroup (patients in Killip class 1, patients
without diabetes mellitus, and patients with successful
reperfusion), we planned to enroll 940 patients. Interim
analysis with regard to safety was planned and performed
after inclusion of 240 patients, and the study was continued
according to protocol. Enrollment of patients started in
April 1998 and ended September 2001.
RESULTS
Study population. Of the 940 patients enrolled, 476 pa-
tients were randomly assigned to the GIK group, and 464
patients to the control group. Table 1 shows clinical and
demographic characteristics of the groups; with the excep-
tion of male gender, there were no statistically significant
differences between both groups. The GIK infusion was
started 15 to 20 min after admission. Average door-to-
balloon time was 45 min in the GIK group and 48 min in
the control group. After coronary angiography, 860 patients
(90.5%) underwent PTCA, 38 patients (4.0%) were referred
for coronary artery bypass grafting within 7 days after initial
stabilization, and 42 patients (4.5%) were treated conserva-
tively. There were no major differences in blood-glucose
levels between the GIK group and the control group at
admission (median blood-glucose level 8.5 mmol/l in both
groups) and 16 h after admission (median blood-glucose
level 7.7 mmol/l in the GIK group and 8.1 mmol/l in the
control group). Side effects such as hypoglycemia, hyperkali-
emia, and severe phlebitis were not observed.
Mortality. Of the 940 patients, 50 (5.3%) had died at 30
days, 23 of 476 patients (4.8%) in the GIK group versus 27
of 476 patients (5.8%) in the control group (RR 0.82, 95%
confidence interval [CI] 0.46 to 1.46) (Table 2, Fig. 1). In
856 of the 940 patients (91.1%) without signs of heart
failure (HF) (Killip class 1), the mortality rate was 5 of 426
patients (1.2%) in the GIK group versus 18 of 430 patients
(4.2%) in the control group (RR 0.28, 95% CI 0.1 to 0.75)
(Tables 2 and 3, Fig. 2). In this subgroup of patients, a
higher number of patients died of HF in the control group
Abbreviations and Acronyms
CI  confidence interval
ECLA  Estudios Cardiologicos Latinoamerica pilot
trial
GIK  glucose-insulin-potassium
HF  heart failure
MI  myocardial infarction
PTCA  primary coronary transluminal angioplasty
RR  relative risk
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(0.7% in the GIK group vs. 2.8% in the control group)
(Table 4). In the 84 patients (8.9%) with signs of HF (Killip
class 2), mortality rate was 18 of 50 patients (36%) in the
GIK group versus 9 of 34 patients (26.5%) in the control
group (RR 1.44, 95% CI 0.65 to 3.22). In this subgroup of
patients, 34.0% in the GIK group versus 20.6% in the
control group died of HF (Table 4). In 99 patients (10.5%)
with a history of diabetes mellitus, 2 of the 50 patients
(4.0%) in the GIK group died versus 6 of 49 patients
(12.2%) in the control group (RR 0.30, 95% CI 0.06 to
1.56). Mortality rates in the other predefined subgroups are
shown in Table 2. Figure 3 shows RRs and 95% CIs in each
subgroup. Causes of death are represented in Table 4.
Recurrent infarction occurred in 11 patients: 4 patients
(0.8%) in the GIK group and 7 patients (1.5%) in the
control group (RR 0.55, 95% CI 0.16 to 1.90) (Table 5).
The composite end point was comparable in the GIK group
and the control group (RR 0.79, 95% CI 0.50 to 1.24). In
patients without HF (Killip class 1), the composite end
point showed a significant advantage of GIK (RR 0.48, 95%
CI 0.27 to 0.87). Gender, age, previous MI, history of
diabetes mellitus, smoking status, Killip class, anterior MI,
multivessel disease, and successful reperfusion were associ-
ated with 30-day mortality in the overall population. In
multivariate analysis in the overall study population, age,
previous MI, Killip class, and successful reperfusion were
independent prognostic factors for 30-day mortality. After
adjustment for these factors in the overall population, RR of
mortality with GIK became 0.61 (95% CI 0.34 to 1.10). In
the group of Killip class 1 patients, the beneficial effect of
GIK remained significant with an adjusted RR of 0.28 (95%
CI 0.10 to 0.77).
DISCUSSION
The 30-day mortality rate was lower in the GIK group
(4.8%) compared with the control group (5.8%), but was not
statistically significant. In the large predefined subgroup of
856 patients without signs of HF (Killip class 1), a signif-
icant reduction of mortality was seen (1.2% in the GIK
group compared with 4.2% in the control group). In the 84
patients with signs of HF (Killip class 2), we did not
observe a significant difference in mortality between the two
groups. In the other predefined subgroups, such as patients
with successful reperfusion, GIK did not result in a signif-
icant beneficial effect (p 0.14) (Table 2). The definition of





Age, yrs 59.9  11.9 60.8  12.0
Men 351 (73.7) 368 (79.3)
Referred patients 201 (42.3) 180 (38.8)
Body mass index, kg/m2 (mean  SD) 26.7  3.8 27.0  4.0
Previous MI 52 (10.9) 53 (11.4)
Previous coronary angioplasty 22 (4.7) 24 (5.2)
Previous CABG 14 (2.9) 12 (2.6)
History of stroke 17 (3.6) 15 (3.2)
Diabetes mellitus 50 (10.5) 49 (10.6)
Hypertension 134 (28.2) 130 (28.0)
Hyperlipidemia 94 (19.7) 95 (20.5)
Currently smoker 225 (47.3) 237 (51.1)
Positive family history 195 (41.0) 179 (38.6)
Time to admission, min (interquartile range)* 150 (100–215) 150 (105–234)
Door-to-balloon time, min (interquartile range) 45 (31–64) 48 (34–69)
Killip class 1 426 (89.5) 430 (92.7)
Killip class 2 24 (5.0) 14 (3.0)
Killip class 3 14 (2.9) 14 (3.0)
Killip class 4 12 (2.5) 6 (1.3)
Anterior MI 250 (52.9) 224 (49.1)
Multivessel disease 249 (52.3) 242 (52.2)
PTCA 436 (91.6) 424 (91.4)
In-hospital CABG† 19 (4.0) 19 (4.1)
TIMI 3 flow 459 (96.4) 435 (93.8)
Successful reperfusion‡ 394 (82.8) 384 (82.8)
Intra-aortic balloon pump 45 (9.5) 42 (9.1)
Mechanical ventilation 12 (2.5) 4 (0.9)
Stent§ 255 (58.5) 236 (55.7)
Glycoprotein IIb/IIIa receptor blocker§ 96 (22.1) 109 (25.7)
Data are number (%) unless otherwise indicated. *Time to admission denotes time between onset of symptoms and until
admission; †in-hospital CABG denotes CABG defined as patients treated initially conservative. followed by elective CABG
within 7 days; ‡successful reperfusion denotes TIMI 3 flow and blush grade 2 or 3; §percentage defined as the percentage of the
patients that underwent PTCA.
CABG coronary artery bypass grafting; GIK glucose-insulin-potassium; MImyocardial infarction; PTCA primary
coronary transluminal angioplasty; TIMI  Thrombolysis In Myocardial Infarction.
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several subgroups, particularly with small numbers of pa-
tients, carries the risk of finding significance due to chance
alone, that is, either beneficial or detrimental. Nevertheless,
the principal finding of benefit of GIK in patients without
signs of HF and, in particular, the RR and CI (Fig. 3) are
unlikely caused by chance.
Previous studies with GIK. The beneficial effect of GIK
in acute MI has been suggested by several clinical studies
(2,5). The first small study that combined GIK with
thrombolysis reported an improved ejection fraction and
wall motion (9). In the Estudios Cardiologicos Latino-
america (ECLA) pilot trial, a beneficial effect on in-hospital
mortality was observed primarily in the subgroup of patients
in which GIK was combined with thrombolysis (19).
However, in the Polish-Glucose-Insulin-Potassium (Pol-
GIK) trial, with 954 patients using low-dose GIK, mortality
in the GIK group was even significantly higher than in the
control group (8.9% vs. 4.8%, p  0.01) (23).
When compared with the results of the ECLA pilot trial
of the subgroup of 252 patients treated with GIK and
reperfusion, the mortality rate reduction in our study, that
is, 1% in the overall population, was much smaller (19).
Several facts could explain the difference between both
studies. First, all patients in both groups of our study were
treated with PTCA compared with prior studies that used
preferentially thrombolysis or no reperfusion therapy. Sec-
ond, the mortality rate is low, due to the effect of our
standard care for patients with acute MI, that is, the short
time from onset of symptoms to treatment, the use of
additional therapies, and a high rate of stenting (57.1%).
Third, in our study the number of patients with signs of HF
at admission was much higher than in the ECLA pilot trial.
In this subgroup of patients, an increased mortality rate was
observed in our study. It is harder to reduce the mortality
even more in a population with such a low mortality rate.
The mortality rate in the control group in the ECLA pilot
trial was 15.2%, a percentage that was even higher than the
mortality rate of patients in the control group of patients
that did not receive reperfusion therapy.
GIK in patients with signs of HF. The effect of GIK
infusion in patients with signs of HF (Killip class 2) is
uncertain. Despite liberal use of intra-aortic balloon pump-




Mortality (%) RR (95% CI) p Value
All patients 23/476 (4.8) 27/464 (5.8) 0.82 (0.46–1.46) 0.50
60 yrs 7/235 (3.0) 6/204 (2.9) 1.01 (0.34–3.07) 0.98
60 yrs 16/241 (6.6) 21/260 (8.1) 0.81 (0.41–1.59) 0.54
Men 9/351 (2.6) 16/368 (4.3) 0.58 (0.25–1.33) 0.19
Women 14/125 (11.2) 11/96 (11.5) 0.98 (0.42–2.26) 0.95
Time to admission 180 min 9/304 (3.0) 13/288 (4.5) 0.65 (0.27–1.53) 0.32
Time to admission 180 min 14/172 (8.1) 14/176 (8.0) 1.03 (0.47–2.20) 0.94
Diabetes mellitus 2/50 (4.0) 6/49 (12.2) 0.30 (0.06–1.56) 0.16
No diabetes mellitus 21/426 (4.9) 21/415 (5.1) 0.97 (0.52–1.81) 1.00
Killip class 1 5/426 (1.2) 18/430 (4.2) 0.27 (0.10–0.74) 0.01
Killip class 2 3/24 (12.5) 2/14 (14.3) 0.86 (0.13–5.87) 0.88
Killip class 3 7/14 (50.0) 4/14 (28.6) 2.50 (0.53–11.93) 0.25
Killip class 4 8/12 (66.7) 3/6 (50.0) 2.00 (0.27–14.78) 0.49
Anterior MI 18/250 (7.2) 19/224 (8.5) 0.84 (0.43–1.64) 0.60
Non-anterior MI 5/226 (2.2) 8/240 (3.3) 0.66 (0.21–2.04) 0.46
Multivessel disease 19/249 (7.6) 24/242 (9.9) 0.75 (0.40–1.41) 0.37
Single-vessel disease 4/227 (1.8) 3/222 (1.4) 1.31 (0.29–5.91) 0.73
TIMI 3 flow 17/459 (3.7) 20/435 (4.6) 0.80 (0.41–1.55) 0.51
No TIMI 3 flow 6/17 (35.3) 7/29 (24.1) 1.71 (0.46–6.35) 0.51
Successful reperfusion* 9/394 (2.3) 16/384 (4.2) 0.54 (0.24–1.23) 0.14
No successful reperfusion 14/82 (17.1) 11/80 (13.8) 1.29 (0.55–3.05) 0.56
Relative risks were determined by dividing the cumulative incidence rates in the GIK group and the control group. *Successful
reperfusion denotes TIMI 3 flow and blush grade 2 or 3.
CI  confidence interval; GIK  glucose-insulin-potassium; MI  myocardial infarction; RR  relative risk; TIMI 
Thrombolysis In Myocardial Infarction.
Figure 1. Kaplan-Meier curve showing cumulative survival of patients
randomized to glucose-insulin-potassium (GIK) group or control group.
Differences between the groups were nonsignificant (unadjusted p 0.50).
The p value was determined with the use of the log-rank test. Solid line
 GIK group; dotted line  control group.
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ing (9.3%), more patients in the GIK group needed me-
chanical ventilation (2.5% in the GIK group vs. 0.9% in the
control group). Heart failure was an important cause of
death in patients admitted with Killip class 2 (Table 5).
Therefore, it is a possibility that in some patients the
potential positive effects of GIK on metabolism were
overruled by a negative effect of the volume load on the
hemodynamic state (24 –26). For a patient of 80 kg in our
study, our infusion rate resulted in the infusion of 1,920
ml in 8 h. Administering such a volume load to patients
with an impaired left ventricular function may induce
hemodynamic instability, even though the metabolic
effect may be beneficial. However, we did not expect this
infusion rate to be detrimental because in early studies
hemodynamic disturbances, such as pulmonary conges-
tion, dyspnea, and edema, occurred in only 1% to 3% of
patients treated with GIK (6). In experimental and
clinical studies, the infusion of insulin and glucose did
increase the contractile force (27–29), although others
found that GIK made no differences on hemodynamic
parameters (8).
Studies with strict metabolic regulation. In the Diabetes
Insulin-Glucose in Acute Myocardial Infarction (DIGAMI)
study with 620 patients with an acute MI and diabetes
mellitus or glucose at admission 11.0 mmol/l, the com-
bination of insulin-glucose infusion followed by intensive
insulin treatment resulted in better glycemic control in the
insulin-glucose group (20). At one-year follow-up, mortal-
ity was lower in the insulin-glucose group, with 18.6%
versus 26.1% in the control group (p  0.03) (30).
It is suggested that GIK is mainly beneficial by the effects
of insulin on the myocardium and the whole body (31,32).
The results of a study of intensive insulin therapy in
critically ill patients to maintain blood glucose below 6.1
mmol/l gives direction for future research in which meta-
bolic interventions in acute MI are directed towards nor-
moglycemia (33).
GIK and time to reperfusion. It has been postulated that
through reduction in the extent of ischemic myocardial
damage and suppression of free fatty acid levels, GIK
therapy prevents reperfusion injuries that may occur after
successful revascularization (6). Protection of the cell mem-
brane of ischemic cardiac cells may also improve reflow after
reperfusion and protect against no-reflow phenomenon by
reducing cell swelling and microvascular compression. It has
been estimated that GIK therapy has the potential to
protect ischemic myocardium before reperfusion for 10 h or
even longer (34). Our study offered the opportunity to
analyze the effect of GIK in patients with different ischemic
time, that is, time to admission and door-to-balloon time.
Table 3. Effect of GIK on 30-Day Mortality in Patients With Killip Class 1, 2, 3, and 4

















60 yrs 1/217 (0.5) 4/192 (2.1) 0/10 (—) 1/5 (20.0) 3/4 (75.0) 1/6 (16.7) 3/4 (75.0) 0/1 (—)
60 yrs 4/209 (1.9) 14/238 (5.9)* 3/14 (21.4) 1/9 (11.1) 4/10 (40.0) 3/8 (37.5) 5/8 (62.5) 3/5 (60.0)
Men 2/319 (0.6) 11/347 (3.2)* 2/18 (11.1) 1/9 (11.1) 1/7 (14.3) 2/7 (28.6) 4/7 (57.1) 2/5 (40.0)
Women 3/107 (2.8) 7/83 (8.4) 1/6 (16.7) 1/5 (20.0) 6/7 (85.7) 2/7 (28.6) 4/5 (80.0) 1/1 (100.0)
Time to admission 180 min 2/276 (0.7) 8/264 (3.0) 2/16 (12.5) 0/8 (—) 2/5 (40.0) 4/12 (33.3) 3/7 (42.9) 1/4 (25.0)
Time to admission 180 min 3/150 (2.0) 10/166 (6.0) 1/8 (12.5) 2/6 (33.3) 5/9 (55.6) 0/2 (—) 5/5 (100.0) 2/2 (100.0)
Diabetes mellitus 0/44 (—) 4/43 (9.3) 2/3 (66.7) 0/1 (—) 0/2 (—) 1/3 (33.3) 0/1 (—) 1/2 (50.0)
No diabetes mellitus 5/382 (1.3) 14/387 (3.6)* 1/21 (4.8) 2/13 (15.4) 7/12 (58.3) 3/11 (27.3) 8/11 (72.7) 2/4 (50.0)
Anterior MI 3/218 (1.4) 13/206 (6.3)† 2/12 (16.7) 1/6 (16.7) 7/12 (58.3) 3/8 (37.5) 6/8 (75.0) 2/4 (50.0)
Non-anterior MI 2/208 (1.0) 5/224 (2.2) 1/12 (8.3) 1/8 (12.5) 0/2 (—) 1/6 (16.7) 2/4 (50.0) 1/2 (50.0)
Multivessel disease 3/212 (1.4) 15/219 (6.8)† 3/16 (18.8) 2/8 (25.0) 6/10 (60.0) 4/11 (36.4) 7/11 (63.6) 3/4 (75.0)
Single-vessel disease 2/214 (0.9) 3/211 (1.4) 0/8 (—) 0/6 (—) 1/4 (25.0) 0/3 (—) 1/1 (100.0) 0/2 (—)
TIMI 3 flow 5/416 (1.2) 13/404 (3.2)* 1/21 (4.8) 1/12 (8.3) 6/13 (46.2) 4/14 (28.6) 5/9 (55.6) 2/5 (40.0)
No TIMI 3 flow 0/10 (—) 5/26 (19.2) 2/3 (66.7) 1/2 (50.0) 1/1 (100.0) 0/0 (—) 3/3 (100.0) 1/1 (100.0)
Successful reperfusion‡ 3/362 (0.8) 12/364 (3.3)* 1/19 (5.3) 1/10 (10.0) 3/8 (37.5) 3/8 (37.5) 2/5 (40.0) 0/2 (—)
No successful reperfusion 2/64 (3.1) 6/66 (9.1) 2/5 (40.0) 1/4 (25.0) 4/6 (66.7) 1/6 (16.7) 6/7 (85.7) 3/4 (75.0)
Relative risks were determined by dividing the cumulative incidence rates in the GIK group and the control group. *p value of RR  0.05; †p value of RR  0.01. ‡Successful
reperfusion denotes TIMI 3 flow and blush grade 2 or 3.
GIK  glucose-insulin-potassium; MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
Figure 2. Kaplan-Meier curve showing cumulative survival of Killip 1 class
patients randomized to glucose-insulin-potassium (GIK) group or control
group. Differences between the groups were significant (unadjusted p 
0.01). P value was determined with the use of the log-rank test. Solid line
 GIK group; dotted line  control group.
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We could not find a clear relation between the time delays
and the effect of GIK (Tables 2 and 3) (34).
Adverse effects. With the possible exception of volume
overload in patients with Killip class 2, there were no
adverse effects of GIK. Phlebitis did not occur in our study,
even though the majority of patients received the infusion
via a peripheral venous line. It is most likely that this is due
to the short infusion period, maximally 12 h. In the ECLA
pilot trial, 17% developed mild phlebitis, and only 2%
developed severe phlebitis after 24 h of GIK infusion (19).
Study limitations. With the observed low mortality rates
in the GIK group and control group in the overall popula-
tion, our study could not detect a significant difference in
mortality. A more realistic risk reduction for future research
may be a risk reduction of 30% in patients with Killip class
1. Therefore, in future studies, over 2,000 patients have to
be included. By including 940 patients in our present study,
the number of patients in some of the subgroups, such as in
patients with a history of diabetes mellitus, were too small to
draw definite conclusions. The subgroups of patients in our
study were predefined, but we did not use a method to
correct for multiple comparisons to analyze them. The role
of GIK in patients with signs of HF is unclear, and the
volume load may be detrimental. A more tailored approach
in patients with HF at admission seems warranted, such as
the admission of glucose 30%, an infusion of no more than
Table 4. Causes of Death in GIK Group and Control Group










Myocardial rupture 1 (0.2) 1 (0.2) — 2 (5.9)
Recurrent infarction — 1 (0.2) 1 (2.0) —
Heart failure 3 (0.7) 12 (2.8) 17 (34.0) 7 (20.6)
Sudden death — 3 (0.7) — —
Non-cardiac 1 (0.2) 1 (0.2) — —
All causes 5 (1.2) 18 (4.2) 18 (36.0) 9 (26.5)
Data are number (%). Percentage defined as the percentage of all patients in the subgroup.
GIK  glucose-insulin-potassium.
Figure 3. Relative risk (dots) and 95% confidence intervals (lines) of glucose-insulin-potassium (GIK) on 30-day mortality in overall population and in
predefined subgroups. MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
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500 ml, or a period of infusion of 12 to 24 h (6).
Alternatively, in these patients the GIK infusion should be
combined with other measures, such as continuous moni-
toring of hemodynamic parameters (28). Our study had an
open-label design, because the need to administer a large
volume of fluid, frequent blood-glucose monitoring, and
adjustments of the insulin dose in the study group is both
unethical and unpractical to organize in a placebo-
controlled study.
Conclusions. Glucose-insulin-potassium infusion as ad-
junctive therapy to PTCA in acute MI seems promising. In
the large subgroup of patients without signs of HF (over
90% of all patients), we did find a significant beneficial
effect. The favorable results of GIK in patients without signs
of HF did encourage us to start a large, multicenter,
randomized trial to determine the optimal metabolic man-
agement in patients with a heart rate 90 beats/min, a
systolic blood pressure 100 mm Hg, and no third heart
sound or pulmonary rales. Alternative regimens for meta-
bolic modulation may be necessary for patients with signs of
HF.
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